Literature DB >> 1139236

Hyper-transaminasemia with heparin therapy.

M Sonnenblick, A Oren, W Jacobsonn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1139236      PMCID： PMC1673676          DOI： 10.1136/bmj.3.5975.77

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  1 in total

1.  In vivo effect of heparin on acid and alkaline ribonuclease activities of mouse liver.

Authors:  G DE LAMIRANDE; G WEBER; A CANTERO
Journal:  Am J Physiol       Date:  1956-02
  1 in total
  5 in total

1.  Effects of Bivalirudin and Unfractionated Heparin on Liver and Renal Function in Chinese Patients with Coronary Artery Disease Undergoing Coronary Angiography with/without Percutaneous Coronary Intervention.

Authors:  Qiaowei Jia; Jia Hu; Wenfeng Ji; Liansheng Wang; Enzhi Jia
Journal:  J Clin Transl Hepatol       Date:  2021-04-09

2.  Enoxaparin-induced hepatotoxicity: an under-recognised complication of enoxaparin therapy.

Authors:  Katie Ann Pivarnik; Fred Schiffman; James Sullivan; Arkadiy Finn
Journal:  BMJ Case Rep       Date:  2016-09-23

Review 3.  A comparative review of the adverse effect profiles of heparins and heparinoids.

Authors:  L C Borris; M R Lassen
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

4.  A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trial.

Authors:  B A Howell; S Q Siler; L K M Shoda; Y Yang; J L Woodhead; P B Watkins
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-02-05

Review 5.  Enoxaparin-Induced Liver Injury: Case Report and Review of the Literature and FDA Adverse Event Reporting System (FAERS).

Authors:  Katherine J Hahn; Shannon J Morales; James H Lewis
Journal:  Drug Saf Case Rep       Date:  2015-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.